<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992585</url>
  </required_header>
  <id_info>
    <org_study_id>PTBD retro 002</org_study_id>
    <nct_id>NCT04992585</nct_id>
  </id_info>
  <brief_title>Primary Versus Secondary Metal Stent Implantation in PTBD</brief_title>
  <official_title>Primary Versus Secondary Metal Stent Implantation in PTBD in Patients With Extrahepatic Malignant Bile Duct Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theresienkrankenhaus und St. Hedwig-Klinik GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universit√§tsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Theresienkrankenhaus und St. Hedwig-Klinik GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to compare percutaneous transhepatic biliary drainage (PTBD) with primary metal&#xD;
      stent implantation (one stage-procedure) with PTBD with secondary metal stent implantation in&#xD;
      terms of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous transhepatic biliary interventions (PBI) are used in biliary tract diseases when&#xD;
      endoscopic access was not successful or not possible due to anatomical changes after&#xD;
      abdominal surgery. Self-expandible metal stents (SEMS) can be applied percutaneously in&#xD;
      patients with malignant extrahepatic bile duct obstruction. In this setting, PTBD is usually&#xD;
      performed as a two step-procedure with primary drainage of the accumulated bile fluid by an&#xD;
      external or an external/internal plastic stent and a secondary metal stent implantation at an&#xD;
      interval of a few days. PTBD with primary metal stent implantation might shorten the hospital&#xD;
      stay and is therefore equal to the increasingly used method of endoscopic ultrasound-guided&#xD;
      biliary drainage (EUS-BD). EUS-BD offers a one step-procedure with primary metal stent&#xD;
      implantation which is probably associated with lesser adverse events (AE) than PTBD with&#xD;
      secondary metal stent implantation. However, it is not clear whether PTBD with primary metal&#xD;
      stent implantation shows fewer adverse events than PTBD with secondary stent implantation.&#xD;
      The aim of this study is to retrospectively analyze the prospectively collected data of PTBDs&#xD;
      with primary or secondary metal stent implantation in patients with proximal and distal&#xD;
      malignant bile duct obstruction. The focus of this single center study will be to compare the&#xD;
      two approaches in terms of adverse events. Adverse events in PTBD might range from very mild&#xD;
      to fatal. Therefore, the severity of the adverse events has been considered in the&#xD;
      calculation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2011</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Retrospective comparison of two similar interventions with small modification</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the intervention until 30 days after</time_frame>
    <description>All adverse events which have been documented in the medical record were analyzed and classified as mild, moderate, severe or fatal/death according to the AE severity grading system of the American Society of Gastrointestinal Endoscopy (ASGE)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bile Duct Obstruction</condition>
  <condition>Extrahepatic Cholestasis</condition>
  <arm_group>
    <arm_group_label>PTBD with primary metal stent implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTBD with primary metal stent implantation is performed in the same session as a one step-procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTBD with secondary metal stent implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTBD with secondary metal stent implantation is performed as a two step-procedure with metal stent implantation 3 to 7 days after previous percutaneous transhepatic biliary drainage and insertion of a plastic catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous transhepatic implantation of self-expandable metal stent</intervention_name>
    <description>A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease</description>
    <arm_group_label>PTBD with primary metal stent implantation</arm_group_label>
    <arm_group_label>PTBD with secondary metal stent implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PTBD with metal stent implantation into the extrahepatic bile duct&#xD;
&#xD;
          -  malignant and non-resectable extrahepatic bile duct obstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  benign extrahepatic bile duct obstruction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Schmitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Theresienkrankenhaus Mannheim, University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tertiary referral hospital: Theresienkrankenhaus und St. Hedwig Hospital, Academic</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Sharaiha RZ, Khan MA, Kamal F, Tyberg A, Tombazzi CR, Ali B, Tombazzi C, Kahaleh M. Efficacy and safety of EUS-guided biliary drainage in comparison with percutaneous biliary drainage when ERCP fails: a systematic review and meta-analysis. Gastrointest Endosc. 2017 May;85(5):904-914. doi: 10.1016/j.gie.2016.12.023. Epub 2017 Jan 4. Review.</citation>
    <PMID>28063840</PMID>
  </reference>
  <reference>
    <citation>Venkatanarasimha N, Damodharan K, Gogna A, Leong S, Too CW, Patel A, Tay KH, Tan BS, Lo R, Irani F. Diagnosis and Management of Complications from Percutaneous Biliary Tract Interventions. Radiographics. 2017 Mar-Apr;37(2):665-680. doi: 10.1148/rg.2017160159. Review. Erratum in: Radiographics. 2017 May-Jun;37(3):1004. Damodharan, Karthik [corrected to Damodharan, Karthikeyan].</citation>
    <PMID>28287940</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027.</citation>
    <PMID>20189503</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bile Duct Obstruction</keyword>
  <keyword>Self Expandable Metallic Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Extrahepatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

